Background: Patient telephone advice in rheumatology is an unremunerated service that is a key component of good patient care i116 Downloaded from https://academic.oup.
blood tests carried out. Sixty-seven patients were having their blood monitoring at the correct intervals. Twenty-three patients were being over monitored and having monthly blood tests despite being on a stable dose for over a year; of these one, had requested to remain on monthly blood tests for their own reassurance. Five patients after increasing their dose of MTX had blood tests outside the two week guidance (three patients at 1 week and two patients over 2 weeks). Three patients did not attend for blood monitoring and MTX was subsequently stopped. Two patients were having blood tests more frequently due to the clinicians request (elevated liver function tests (LFTs) and a history of neutropenia). Seven patients had blood abnormalities, four were related to raised LFTs and three to neutropenia. MTX was appropriately stopped in these patients. Conclusion: This audit enabled us to collect data on patient safety with MTX blood monitoring. All patients were having the correct blood tests carried out and MTX was stopped when blood abnormalities were identified. There were discrepancies in terms of the frequency of blood monitoring when a patient increased their dose or had been on a stable dose for over 1 year. We need to have mechanisms in place to ensure patients have their blood tests at the recommended intervals to ensure patient safety. By auditing data on drug safety indicators in rheumatology we can demonstrate that we are applying clinical governance within our speciality. Background: Intra-articular steroid injection is a key aspect in the management of rheumatology patients. In the majority of cases, this procedure occurs without incident. There are, however, recognized potential risks that patients should be informed of. A wide range of approach to injections exists throughout different rheumatology centres. A patient information leaflet produced by the Arthritis Research Council (ARC) for IA steroid injections was updated last year and two of the changes from previous were that patients should have (i) blood pressure and (ii) blood sugar checked prior to injection as these can become altered following the procedure. A literature review did not reveal any evidence to warrant this statement. Abnormalities pre-injection could result in a delay which not only lengthens patients suffering but also affects clinic waiting times. Checking these two values prior to injection was not routine practice in rheumatology in Belfast so an audit sought to establish the practices of members of the Irish Society of rheumatologists. Methods: 22 consultant members of the Irish Society of Rheumatology completed a questionnaire investigating a wide range of aspects of approach to IA steroid injection. Results: Results showed 32% used the ARC leaflet discussed above. Most used verbal consent and half documented allergy status prior to injection. Most consented for risk of infection, bleeding/bruising, no improvement, potential worsening of pain and damage to nearby tissues. Only 9% consented for effect on blood pressure but 73% discussed raised blood sugars in diabetics. 14% checked blood pressure prior to injection and none recommended follow-up after injection. None checked blood sugar prior to injection, however, 14% recommended monitoring of blood sugar levels for 48 hours after injection. Information was also gained on aseptic technique. All washed hands prior to injection but 18% were not bare below the elbows routinely and 23% did not use sterile gloves. 23% used an alcohol wipe alone rather than cleaning solutions. When ultrasound scanning was used for injection, most used sterile gel and sterile probe covers. Evidence as to the need for degree of aseptic technique is unclear and would be an interesting topic to audit in the future. Conclusion: In terms of blood pressure and blood glucose it was evident from the audit results that it was not common national practice to check these prior to steroid injection as the ARC leaflet suggested. The audit findings were communicated with the authors of the ARC leaflets and a reply received stated that our information had been taken into consideration and agreed with. This has resulted in plans to remove this statement from future versions of the patient information leaflet thereby hopefully reducing any unnecessary delay in those requiring IA steroid injection and any further potential joint destruction. Disclosure statement: The authors have declared no conflicts of interest. Conclusion: The quality improvement process involving a rheumatology pharmacist ensured a high proportion had adjusted calcium and eGFR (92%), as well as vitamin D (85%) measured before zoledronate. These patients were already on treatment for osteoporosis and were expected to have adequate calcium and vitamin D intake (dietary and/ or supplementation). However, of those measured, the process flagged up 46% with Vitamin D insufficiency or deficiency for further attention. It also flagged up 23.5% in CKD3 for close monitoring. Therefore, to ensure optimal outcomes with treatment we recommend that all patients being considered for zoledronate have their renal and bone profile assessed irrespective of previous treatment status. 
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